Imbalanced mechanistic target of rapamycin C1 and C2 activity in the cerebellum of Angelman syndrome mice impairs motor function

The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
Jiandong SunXiaoning Bi

Abstract

Angelman syndrome (AS) is a neurogenetic disorder caused by deficiency of maternally expressed ubiquitin-protein ligase E3A (UBE3A), an E3 ligase that targets specific proteins for proteasomal degradation. Although motor function impairment occurs in all patients with AS, very little research has been done to understand and treat it. The present study focuses on Ube3A deficiency-induced alterations in signaling through the mechanistic target of rapamycin (mTOR) pathway in the cerebellum of the AS mouse model and on potential therapeutic applications of rapamycin. Levels of tuberous sclerosis complex 2 (TSC2), a negative regulator of mTOR, were increased in AS mice compared with wild-type mice; however, TSC2 inhibitory phosphorylation was also increased. Correspondingly, levels of phosphorylated/active mTOR were increased. Phosphorylation of the mTORC1 substrates S6 kinase 1 (S6K1) and S6 was elevated, whereas that of the mTORC2 substrates AKT and N-myc downstream regulated 1 was decreased, suggesting enhanced mTORC1 but inhibited mTORC2 signaling. Semi-chronic treatment of AS mice with rapamycin not only improved their motor performance but also normalized mTORC1 and mTORC2 signaling. Furthermore, inhibitory phosphorylation of ...Continue Reading

Citations

Nov 13, 2015·Expert Opinion on Therapeutic Targets·Xiaoning BiMichel Baudry
Feb 15, 2016·Trends in Neurosciences·Michel Baudry, Xiaoning Bi
Jan 14, 2016·Wiener medizinische Wochenschrift·Wen-Hann Tan, Lynne M Bird
Jan 7, 2016·Frontiers in Molecular Neuroscience·Anne BieverEmma Puighermanal
Nov 21, 2015·Epigenomics·Janine M LaSalleStormy J Chamberlain
Oct 7, 2015·Frontiers in Neuroscience·Gabrielle L Sell, Seth S Margolis
May 14, 2016·Cellular and Molecular Life Sciences : CMLS·Jiandong SunXiaoning Bi
Jul 28, 2016·Biological Psychiatry·Eunee LeeEunjoon Kim
Jul 2, 2016·Journal of Neurochemistry·Susana R Louros, Emily K Osterweil
Mar 25, 2017·International Journal of Molecular Sciences·Juliana MagdalonAndréa L Sertié
Nov 20, 2016·American Journal of Medical Genetics. Part C, Seminars in Medical Genetics·Wen-Hann Tan, Lynne M Bird
Mar 1, 2018·Annual Review of Neuroscience·Kellen D WindenMustafa Sahin
Feb 23, 2020·The FEBS Journal·Carina MarangaSimão Teixeira da Rocha
Dec 24, 2019·Journal of Neuroscience Research·Xin Yang
Feb 10, 2017·Oncotarget·Jiandong SunXiaoning Bi
Dec 19, 2019·International Journal of Molecular Sciences·Ekaterina A TrifonovaAlex V Kochetov
Aug 21, 2020·Learning & Memory·Maria N Schultz, Jacqueline N Crawley
Jan 29, 2019·Frontiers in Molecular Neuroscience·Simon Jesse LopezJanine M LaSalle
Jun 28, 2015·Oncotarget·Xiaoning BiMichel Baudry
Oct 21, 2015·The Journal of Clinical Investigation·Caroline F BruinsmaYpe Elgersma
Sep 15, 2018·Inflammation and Regeneration·Kiyomi Tsuji-Tamura, Minetaro Ogawa
May 18, 2021·Biochemistry. Biokhimii︠a︡·Irina S BokshaGulnur Sh Burbaeva
May 17, 2021·Neurochemistry International·Aarti Sharma, Sidharth Mehan
Jul 3, 2021·Frontiers in Molecular Biosciences·Michel BaudryXiaoning Bi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Angelman Syndrome

Angelman syndrome is a neurogenetic imprinting disorder caused by loss of the maternally inherited UBE3A gene and is characterized by generalized epilepsy, limited expressive speech, sleep dysfunction, and movement disorders. Here is the latest research.